Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice
Open accessAbstract
Background & aims Platelet-derived growth factor-β (PDGFB) is a mitogen for hepatic stellate cells (HSCs). We studied the cellular sources of PDGFB and the effects of a high-affinity monoclonal antibody against PDGFB (MOR8457) in mouse models of biliary fibrosis.Methods Cellular sources of PDGFB were identified using quantitative reverse-transcription polymerase chain reaction, biochemical, and immunohistologic methods. Mice with advanced biliary fibrosis, MDR2(Abcb4)-null mice, and C57Bl/6 (control) mice were placed on 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-supplemented diets and were given weekly intraperitoneal injections of MOR8457. Platelets were depleted from MDR2-null mice by injection of an antibody against CD41, or inhibited with diets containing low-dose aspirin. Liver tissues were collected and analyzed by quantitative reverse-transcription PCR and histologic and biochemical analyses.Results Levels of PDGFB protein, but not messenger RNA, were increased in fibrotic livers of MDR2-null mice, compared with control mice. Platelet clusters were detected in the hepatic endothelium, in close proximity to HSCs, and were identified as a source of PDGFB protein in MDR2-null mice. Levels of the PDGFB were increased in serum samples from patients with early stages of liver fibrosis of various etiologies (F1-2, n = 16; P < .05), compared with nonfibrotic liver tissue (F0, n = 12). Depletion of platelets from MDR2-null mice normalized hepatic levels of PDGFB within 48 hours, reducing levels of a marker of HSC activation (α-smooth muscle actin) and expression of genes that promote fibrosis. Diets supplemented with low-dose aspirin reduced circulating serum and hepatic levels of PDGFB and significantly reduced progression of fibrosis in MDR2-null mice over 1 year. MOR8457 produced a dose-dependent decrease in liver fibrosis in MDR2-null mice, reducing collagen deposition by 45% and expression of fibrosis-associated genes by 50%, compared with mice given a control antibody. In vitro, platelets activated freshly isolated HSCs (induction of α-smooth muscle actin and fibrosis-associated genes) via a PDGFB-dependent mechanism. MOR8457 also reduced liver fibrosis in mice placed on DDC-supplemented diets.Conclusions Platelets produce PDGFB to activate HSC and promote fibrosis in MDR2-null mice and mice on DDC-supplemented diets. Antiplatelet therapy or selective inhibition of PDGFB might reduce biliary fibrosis in patients with liver disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In NASH, platelets interact with liver-resident KCs to promote the recruitment of CD8 T cells and NKT cells, depending on interactions between platelet-expressed GPIba and von Willebrand factor, thereby promoting disease.
“In NASH, platelets interact with liver-resident KCs to promote the recruitment of CD8 T cells and NKT cells, depending on interactions between platelet-expressed GPIba and von Willebrand factor, thereby promoting disease.98”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,640 · see citing works
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241 · see citing works
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., Rodríguez, L. A. G., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,217 · see citing works
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099 · see citing works
Primary Sclerosing Cholangitis
Lee, Y., & Kaplan, M. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321406 · Cited by 541 · see citing works
Primary sclerosing cholangitis
Lawson, A. (2014) · Radiopaedia.org · doi:10.53347/rid-26818 · Cited by 446 · see citing works
A New Xenobiotic-Induced Mouse Model of Sclerosing Cholangitis and Biliary Fibrosis
Fickert, P., Stöger, U., Fuchsbichler, A., Moustafa, T., Marschall, H., Weiglein, A. H., Tsybrovskyy, O., Jaeschke, H., Zatloukal, K., Denk, H., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061133 · Cited by 376 · see citing works
Sitia, G., Aiolfi, R., Lucia, P. D., Mainetti, M., Fiocchi, A., Mingozzi, F., Esposito, A., Ruggeri, Z., Chisari, F., Iannacone, M., et al. (2012) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1209182109 · Cited by 318 · see citing works
Popov, Y. V., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23123 · Cited by 297 · see citing works
Self-citationPopov, Y. V., Patsenker, E., Fickert, P., Trauner, M. A., & Schuppan, D. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.06.025 · Cited by 268 · see citing works
Self-citationLiver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice
Czochra, P., Klopcic, B. R. S., Meyer, E., Herkel, J., Garcia-Lazaro, J. F., Thieringer, F. R., Schirmacher, P., Biesterfeld, S., Galle, P. R., Lohse, A. W., et al. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.04.010 · Cited by 244 · see citing works
Hart, C. E., Bailey, M., Curtis, D. A., Osborn, S. G., Raines, E. W., Ross, R., & Forstrom, J. W. (1990) · Biochemistry · doi:10.1021/bi00453a022 · Cited by 228 · see citing works
Kinnman, N., Francoz, C., Barbu, V., Wendum, D., Rey, C., Hultcrantz, R. W., Poupon, R. Y., & Housset, C. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000054178.01162.e4 · Cited by 219 · see citing works
Patsenker, E., Popov, Y. V., Stickel, F., Jonczyk, A., Goodman, S. L., & Schuppan, D. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.009 · Cited by 199 · see citing works
Self-citationPopov, Y. V., Patsenker, E., Stickel, F., Zaks, J., Bhaskar, K. R., Niedobitek, G., Kolb, A., Friess, H., & Schuppan, D. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.021 · Cited by 185 · see citing works
Self-citationNocito, A., Georgiev, P., Dahm, F., Jochum, W., Bäder, M., Graf, R., & Clavien, P. (2007) · Hepatology · doi:10.1002/hep.21516 · Cited by 166 · see citing works
Cao, S., Yaqoob, U., Das, A., Shergill, U., Jagavelu, K., Huebert, R. C., Routray, C., Abdelmoneim, S. S., Vasdev, M. M., Leof, E. B., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41203 · Cited by 161 · see citing works
Transplantation trends in primary biliary cirrhosis
Lee, J., Belanger, A., Doucette, J. T., Stanca, C., Friedman, S., & Bach, N. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.07.015 · Cited by 147 · see citing works
Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats
Yoshiji, H., Noguchi, R., Kuriyama, S., Ikenaka, Y., Yoshii, J., Yanase, K., Namisaki, T., Kitade, M., Masaki, T., & Fukui, H. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00420.2004 · Cited by 145 · see citing works
Popov, Y. V., Sverdlov, D., Sharma, A. K., Bhaskar, K. R., Li, S., Freitag, T. L., Lee, J. D., Dieterich, W., Melino, G., & Schuppan, D. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.040 · Cited by 137 · see citing works
Self-citationPopov, Y., Sverdlov, D. Y., Bhaskar, K. R., Sharma, A. K., Millonig, G., Patsenker, E., Krahenbuhl, S., Krahenbuhl, L., & Schuppan, D. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00394.2009 · Cited by 136 · see citing works
Self-citationThrombocytopenia Exacerbates Cholestasis-Induced Liver Fibrosis in Mice
Kodama, T., Takehara, T., Hikita, H., Shimizu, S., Li, W., Miyagi, T., Hosui, A., Tatsumi, T., Ishida, H., Tadokoro, S., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.054 · Cited by 134 · see citing works
Grappone, C., Pinzani, M., Parola, M., Pellegrini, G., Caligiuri, A., DeFranco, R., Marra, F., Herbst, H., Alpini, G., & Milani, S. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80169-x · Cited by 133 · see citing works
Gong, Y., Huang, Z., Christensen, E., & Gluud, C. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01235.x · Cited by 131 · see citing works
Popov, Y. V., Patsenker, E., Bauer, M. W., Niedobitek, E., Schulze-Krebs, A., & Schuppan, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600030200 · Cited by 101 · see citing works
Self-citationThrombocytopenia Exacerbates Cholestasis-Induced Liver Fibrosis in Mice
小玉, 尚. (2011) · Cited by 98 · see citing works
Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term
Neef, M., Ledermann, M., Saegesser, H., Schneider, V., Widmer, N., Decosterd, L. A., Rochat, B., & Reichen, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.06.015 · Cited by 92 · see citing works
Marra, F., Pinzani, M., DeFranco, R., Laffi, G., & Geñtilini, P. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01261-0 · Cited by 88 · see citing works
Katzenellenbogen, M., Pappo, O., Barash, H., Klopstock, N., Mizrahi, L., Olam, D., Jacob‐Hirsch, J., Amariglio, N., Rechavi, G., Mitchell, L. A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2937 · Cited by 85 · see citing works
Nonaka, H., Tanaka, M., Suzuki, K., & Miyajima, A. (2007) · Developmental Dynamics · doi:10.1002/dvdy.21227 · Cited by 84 · see citing works
Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development
Ogawa, S., Ochi, T., Shimada, H., Inagaki, K., Fujita, I., Nii, A., Moffat, M. A., Katragadda, M., Violand, B. N., Arch, R. H., et al. (2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00718.x · Cited by 63 · see citing works
Self-citationPatsenker, E., Popov, Y. V., Wiesner, M., Goodman, S. L., & Schuppan, D. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.11.011 · Cited by 58 · see citing works
Self-citationSansom, O. J., Stark, L. A., Dunlop, M. G., & Clarke, A. R. (2001) · PubMed · Cited by 50 · see citing works
Sullivan, B. P., Wang, R., Tawfik, O. W., & Luyendyk, J. P. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfq042 · Cited by 46 · see citing works
Momi, S., Pitchford, S. C., Alberti, P. F., Minuz, P., Soldato, P. D., & Gresele, P. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-07-0464 · Cited by 39 · see citing works
Flagged first, then by citations
1 of the 36 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · see citing works
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 772 · see citing works
Hepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677 · see citing works
Self-citationMechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671 · see citing works
The good and the bad collagens of fibrosis – Their role in signaling and organ function
Karsdal, M. A., Nielsen, S. H., Leeming, D. J., Langholm, L. L., Nielsen, M. J., Manon-Jensen, T., Siebuhr, A., Gudmann, N. S., Rønnow, S., Sand, J. M., et al. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.014 · Cited by 509 · see citing works
Self-citationTGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1
Su, J., Morgani, S. M., David, C. J., Wang, Q., Er, E. E., Huang, Y.-H., Basnet, H., Zou, Y., Shu, W., Soni, R. K., et al. (2020) · Nature · doi:10.1038/s41586-019-1897-5 · Cited by 498 · see citing works
An, P., Wei, L.-L., Zhao, S., Sverdlov, D. Y., Vaid, K. A., Miyamoto, M., Kuramitsu, K., Lai, M., & Popov, Y. V. (2020) · Nature Communications · doi:10.1038/s41467-020-16092-0 · Cited by 319 · see citing works
Self-citationIkenaga, N., Peng, Z., Vaid, K. A., Liu, S. B., Yoshida, S., Sverdlov, D., Mikels, A. J., Smith, V., Schuppan, D., & Popov, Y. V. (2017) · Gut · doi:10.1136/gutjnl-2016-312473 · Cited by 298 · see citing works
Self-citationPathological mechanisms and therapeutic outlooks for arthrofibrosis
Usher, K. M., Zhu, S., Mavropalias, G., Carrino, J. A., Zhao, J., & Xu, J. (2019) · Bone Research · doi:10.1038/s41413-019-0047-x · Cited by 291 · see citing works
The PDGF/PDGFR pathway as a drug target
Papadopoulos, N., & Lennartsson, J. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.007 · Cited by 283 · see citing works
Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation
Mandel, J., Casari, M., Stepanyan, M. G., Martyanov, A. A., & Deppermann, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073868 · Cited by 267 · see citing works
Klinkhammer, B. M., Floege, J., & Boor, P. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.008 · Cited by 230 · see citing works
Simon, T. G., Henson, J., Osganian, S., Masia, R., Chan, A. T., Chung, R. T., & Corey, K. E. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.061 · Cited by 180 · see citing works
The PDGF system and its antagonists in liver fibrosis
Borkham‐Kamphorst, E., & Weiskirchen, R. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.10.002 · Cited by 179 · see citing works
Nallagangula, K. S., Nagaraj, S. K., Lakshmaiah, V., & Chandrappa, M. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0083 · Cited by 170 · see citing works
Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy
Cai, X., Wang, J., Wang, J., Zhou, Q., Yang, B., He, Q., & Weng, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104720 · Cited by 167 · see citing works
Platelets: No longer bystanders in liver disease
Chauhan, A., Adams, D., Watson, S. P., & Lalor, P. F. (2016) · Hepatology · doi:10.1002/hep.28526 · Cited by 138 · see citing works
Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention
Lange, N. F., Radu, P., & Dufour, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.025 · Cited by 137 · see citing works
Biology of portal hypertension
McConnell, M. J., & Iwakiri, Y. (2017) · Hepatology International · doi:10.1007/s12072-017-9826-x · Cited by 121 · see citing works
Peng, Z., Ikenaga, N., Liu, S. B., Sverdlov, D. Y., Vaid, K. A., Dixit, R., Weinreb, P. H., Violette, S., Sheppard, D., Schuppan, D., et al. (2016) · Hepatology · doi:10.1002/hep.28274 · Cited by 118 · see citing works
Self-citationUnderstanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116 · see citing works
Lee, M., Chung, G. E., Lee, J., Oh, S., Nam, J. Y., Chang, Y. W., Cho, H., Ahn, H., Cho, Y. Y., Yoo, J., et al. (2017) · Hepatology · doi:10.1002/hep.29318 · Cited by 116 · see citing works
Self-citationAspirin use is associated with lower indices of liver fibrosis among adults in the United States
Jiang, Z. G., Feldbrügge, L., Tapper, E. B., Popov, Y. V., Ghaziani, T., Afdhal, N. H., Robson, S. C., & Mukamal, K. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13515 · Cited by 106 · see citing works
Self-citationAngiodiversity and organotypic functions of sinusoidal endothelial cells
Reiners-Koch, P.-S., Lee, K. H., Goerdt, S., & Augustin, H. G. (2021) · Angiogenesis · doi:10.1007/s10456-021-09780-y · Cited by 97 · see citing works
Platelets as Key Factors in Hepatocellular Carcinoma
Pavlovic, N., Rani, B., Gerwins, P., & Heindryckx, F. (2019) · Cancers · doi:10.3390/cancers11071022 · Cited by 97 · see citing works
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
Simon, T. G., Wilechansky, R. M., Stoyanova, S., Grossman, A., Dichtel, L. E., Lauer, G. M., Miller, K. K., Hoshida, Y., Corey, K. E., Loomba, R. S., et al. (2024) · JAMA · doi:10.1001/jama.2024.1215 · Cited by 96 · see citing works
Wan, Y., Meng, F., Wu, N., Zhou, T., Venter, J. K., Francis, H., Kennedy, L. L., Glaser, T., Bernuzzi, F., Invernizzi, P., et al. (2017) · Hepatology · doi:10.1002/hep.29138 · Cited by 90 · see citing works
Platelets in chronic liver disease, from bench to bedside
Ramadori, P., Klag, T., Malek, N. P., & Heikenwälder, M. F. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.10.001 · Cited by 90 · see citing works
Role of the blood coagulation cascade in hepatic fibrosis
Pant, A., Kopec, A. K., & Luyendyk, J. P. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00402.2017 · Cited by 87 · see citing works
Optimized Mouse Models for Liver Fibrosis
Kim, Y. O., Popov, Y. V., & Schuppan, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6786-5_19 · Cited by 84 · see citing works
Self-citationImmunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81 · see citing works
“Accumulating studies suggest that aspirin exerts anti-in fl ammatory and antitumor effects by inhibiting cyclooxygenase-2 and platelet-derived growth factor signaling, representing a promising and low-cost strategy for the treatment of MASLD [207 – 209].”
Antifibrotic Therapies in the Liver
Schuppan, D., & Mehal, W. Z. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550055 · Cited by 75 · see citing works
Self-citationPlatelets as Modulators of Liver Diseases
Luyendyk, J. P., & Lisman, T. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1604091 · Cited by 73 · see citing works
Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis
Yang, F., Li, H., Li, Y., Hao, Y., Wang, C., Jia, P. P., Chen, X., Ma, S., & Xiao, Z. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108051 · Cited by 71 · see citing works
Torok, N. J., Dranoff, J. A., Schuppan, D., & Friedman, S. L. (2015) · Hepatology · doi:10.1002/hep.27720 · Cited by 70 · see citing works
Self-citationBallerini, P., Contursi, A., Bruno, A., Mucci, M., Tacconelli, S., & Patrignani, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838079 · Cited by 69 · see citing works
Wang, X., Wu, X., Zhang, A., Wang, S., Hu, C., Chen, W., Shen, Y., Tan, R. X., Sun, Y., & Xu, Q. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.042 · Cited by 65 · see citing works
SiRNA-mediated in vivo gene knockdown by acid-degradable cationic nanohydrogel particles
Leber, N., Kaps, L., Aslam, M., Schupp, J., Brose, A., Schaeffel, D., Fischer, K., Diken, M., Strand, D. J., Koynov, K., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.006 · Cited by 63 · see citing works
Self-citationTherapeutic pro-fibrogenic signaling pathways in fibroblasts
Cannito, S., Novo, E., & Parola, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.017 · Cited by 60 · see citing works
NAFLD-Associated HCC: Progress and Opportunities
Geh, D., Anstee, Q. M., & Reeves, H. L. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s272213 · Cited by 61 · see citing works
Miyashita, T., Nakanuma, S., Ahmed, A. K., Makino, I., Hayashi, H., Oyama, K., Nakagawara, H., Tajima, H., Takamura, H., Ninomiya, I., et al. (2015) · European surgery. Supplement/European surgery · doi:10.1007/s10353-015-0363-3 · Cited by 57 · see citing works
Coagulation‐driven platelet activation reduces cholestatic liver injury and fibrosis in mice
Joshi, N., Kopec, A. K., O'Brien, K. M., Towery, K., Cline-Fedewa, H. M., Williams, K. J., Copple, B. L., Flick, M. J., & Luyendyk, J. P. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12770 · Cited by 55 · see citing works
The G Protein-Coupled Bile Acid Receptor TGR5 (Gpbar1) Modulates Endothelin-1 Signaling in Liver
Klindt, C., Reich, M., Hellwig, B., Stindt, J., Rahnenführer, J., Hengstler, J. G., Köhrer, K., Schoonjans, K., Häussinger, D., & Keitel, V. (2019) · Cells · doi:10.3390/cells8111467 · Cited by 55 · see citing works
Macrophages and platelets in liver fibrosis and hepatocellular carcinoma
Casari, M., Siegl, D., Deppermann, C., & Schuppan, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1277808 · Cited by 53 · see citing works
Self-citationTreatment of Hepatic Fibrosis in Mice Based on Targeted Plasmonic Hyperthermia
Ribera, J., Vilches, C., Sanz, V., de Miguel, I., Portolés, I., Córdoba‐Jover, B., Prat, E., Nunes, V., Jiménez, W., Quidant, R., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c00988 · Cited by 49 · see citing works
Jang, H., Lee, Y. B., Moon, H., Chung, J., Nam, J. Y., Cho, E. J., Lee, J., Yu, S. J., Kim, Y. J., Lee, J., et al. (2022) · Hepatology · doi:10.1002/hep.32380 · Cited by 49 · see citing works
Self-citationRole of hemostatic factors in hepatic injury and disease: animal models de‐liver
Kopec, A. K., Joshi, N., & Luyendyk, J. P. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13327 · Cited by 47 · see citing works
Effects of aspirin and enoxaparin in a rat model of liver fibrosis
Li, C.-J., Yang, Z., Shi, X., & Liu, D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i35.6412 · Cited by 47 · see citing works
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Argenziano, M. E., Kim, M. N., Montori, M., Bucchianico, A. D., Balducci, D., Ahn, S. H., & Svegliati‐Baroni, G. (2024) · Hepatology International · doi:10.1007/s12072-024-10692-4 · Cited by 50 · see citing works
Aspirin in Hepatocellular Carcinoma
Ricciotti, E., Wangensteen, K. J., & FitzGerald, G. A. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0758 · Cited by 44 · see citing works
Dong, K., Zheng, Y., Wang, Y., & Guo, Q. (2024) · Scientific Reports · doi:10.1038/s41598-024-80801-8 · Cited by 43 · see citing works
Platelets and Platelet‐Derived Extracellular Vesicles in Liver Physiology and Disease
Balaphas, A., Meyer, J., Sadoul, K., Fontana, P., Morel, P., Gonelle‐Gispert, C., & Bühler, L. H. (2019) · Hepatology Communications · doi:10.1002/hep4.1358 · Cited by 43 · see citing works
Till Death Do Us Part—The Multifaceted Role of Platelets in Liver Diseases
Mußbacher, M., Brunnthaler, L., Panhuber, A., Starlinger, P. P., & Assinger, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063113 · Cited by 41 · see citing works
de Zawadzki, A., Leeming, D. J., Sanyal, A. J., Anstee, Q. M., Schattenberg, J. M., Friedman, S. L., Schuppan, D., & Karsdal, M. A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.039 · Cited by 40 · see citing works
Self-citationPeng, Z., Rothweiler, S., Wei, G., Ikenaga, N., Liu, S. B., Sverdlov, D., Vaid, K. A., Longhi, M. S., Kuang, M., Robson, S. C., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1084 · Cited by 40 · see citing works
Self-citationPharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39 · see citing works
Liver Fibrosis and Inflammation under the Control of ERK2
Jeng, K., Lu, S.-J., Wang, C.-H., & Chang, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113796 · Cited by 39 · see citing works
Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis
Shin, S., Lee, S. H., Lee, M., Kim, J. H., Lee, W., Lee, H. W., Park, M. S., Park, S. W., Kim, T. S., & Choi, D. H. (2020) · Medicine · doi:10.1097/md.0000000000019008 · Cited by 37 · see citing works
Minciună, I., Taru, M. G., Procopeț, B., & Ştefănescu, H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051406 · Cited by 34 · see citing works
Boccatonda, A., Cane, L. D., Marola, L., D'Ardes, D., Lessiani, G., di Gregorio, N., Ferri, C., Cipollone, F., Serra, C., Santilli, F., et al. (2024) · Life · doi:10.3390/life14040473 · Cited by 35 · see citing works
The Provocative Roles of Platelets in Liver Disease and Cancer
Marie, P. K., Fowlkes, N. W., Afshar‐Kharghan, V., Martch, S. L., Sorokin, A. V., Shen, J. P., Morris, V. K., Dasari, A. N., You, N., Sood, A. K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643815 · Cited by 32 · see citing works
Schwarzkopf, K. M., Bojunga, J., Rüschenbaum, S., Martinez, Y., Mücke, M. M., Seeger, F. H., Schoelzel, F., Zeuzem, S., Friedrich‐Rust, M., & Lange, C. M. (2018) · Hepatology Communications · doi:10.1002/hep4.1254 · Cited by 32 · see citing works
Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications
Airola, C., Pallozzi, M., Cerrito, L., Santopaolo, F., Stella, L., Gasbarrini, A., & Ponziani, F. R. (2023) · Cells · doi:10.3390/cells12131712 · Cited by 31 · see citing works
Haghgoo, S. M., Sharafi, H., & Alavian, S. M. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0357 · Cited by 31 · see citing works
Platelets in Non-alcoholic Fatty Liver Disease
Dalbeni, A., Castelli, M., Zoncapè, M., Minuz, P., & Sacerdoti, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.842636 · Cited by 34 · see citing works
Zhou, J., Deng, Y., Yan, L., Zhao, H., & Wang, G. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.06.004 · Cited by 31 · see citing works
Iqbal, U., Dennis, B. B., Li, A. A., Cholankeril, G. T., Kim, D., Khan, M. A., & Ahmed, A. (2018) · Hepatology International · doi:10.1007/s12072-018-9918-2 · Cited by 31 · see citing works
The role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics
Malladi, N., Alam, M. J., Maulik, S. K., & Banerjee, S. (2023) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2023.106766 · Cited by 30 · see citing works
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Lee, H. A., Chang, Y. W., Sung, P. S., Yoon, E. L., Lee, H. W., Yoo, J., Lee, Y., An, J., Song, D. S., Cho, Y. Y., et al. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0186 · Cited by 30 · see citing works
Self-citationMyofibroblast specific targeting approaches to improve fibrosis treatment
Beaven, E., Kumar, R., Bhatt, H. N., Esquivel, S. V., & Nurunnabi, M. (2022) · Chemical Communications · doi:10.1039/d2cc04825f · Cited by 29 · see citing works
Gong, J., Han, J., He, J., Liu, J., Han, P., Wang, Y., Li, M., Li, D., Ding, X., Du, Z., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.65 · Cited by 29 · see citing works
Pavlović, N., Kopsida, M., Gerwins, P., & Heindryckx, F. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119612 · Cited by 28 · see citing works
Role of Fibrin(ogen) in Progression of Liver Disease: Guilt by Association?
Kopec, A. K., & Luyendyk, J. P. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1579655 · Cited by 28 · see citing works
Feldbrügge, L., Jiang, Z. G., Csizmadia, E., Mitsuhashi, S., Tran, S., Yee, E. U., Rothweiler, S., Vaid, K. A., Sévigny, J., Schmelzle, M., et al. (2017) · Purinergic Signalling · doi:10.1007/s11302-017-9590-3 · Cited by 28 · see citing works
Self-citationSun, Z., Zhao, H., Yang, S., Liu, R., Yi, L., Gao, J., Liu, S., Chen, Y., & Zhang, Z. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.10.309 · Cited by 25 · see citing works
Self-citationProgress in research on the roles of TGR5 receptor in liver diseases
Ma, K., Tang, D., Yu, C. J., & Zhao, L. (2021) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.1903547 · Cited by 25 · see citing works
Kyritsi, K., Meng, F., Zhou, T., Wu, N., Venter, J. K., Francis, H., Kennedy, L. L., Onori, P., Franchitto, A., Bernuzzi, F., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.03.013 · Cited by 24 · see citing works
The Important Roles of Natural Killer Cells in Liver Fibrosis
Yang, M. J., Vanderwert, E., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051391 · Cited by 22 · see citing works
New and Old Key Players in Liver Cancer
Cuesta, Á. M., Palao, N., Bragado, P., Gutiérrez-Uzquiza, Á., Herrera, B. M., Sánchez, A., & Porrás, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417152 · Cited by 22 · see citing works
Mahmoud, N. I., Messiha, B. A. S., Salehc, I. G., Abo‐Saif, A. A., & Abdel‐Bakky, M. S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.078 · Cited by 20 · see citing works
Antiplatelet drugs and liver fibrosis
Czajka, P., Przybyłkowski, A. M., Nowak, A., Postula, M. A., Wolska, M., Mirowska-Guzel, D. M., Członkowska, A., & Eyileten, C. (2021) · Platelets · doi:10.1080/09537104.2021.1883574 · Cited by 19 · see citing works
The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis
Jia, T., Xu, T., Smeets, B., Buhl, E. M., Moeller, M. J., Floege, J., Klinkhammer, B. M., & Boor, P. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2022040491 · Cited by 19 · see citing works
Bulboacă, A. E., Porfire, A. S., Rus, V., Nicula, C. A., Bulboacă, C. A., & Bolboaca, S. D. (2022) · Antioxidants · doi:10.3390/antiox11020412 · Cited by 18 · see citing works
Cellular crosstalk during cholestatic liver injury
Thomson, J., Hargrove, L. A., Kennedy, L. L., Demieville, J., & Francis, H. (2017) · Liver Research · doi:10.1016/j.livres.2017.05.002 · Cited by 17 · see citing works
Stellate Cells and Hepatic Fibrosis
Hasegawa, D., Wallace, M. C., & Friedman, S. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800134-9.00004-x · Cited by 17 · see citing works
Yang, Y., Wang, L., Yan, L., Zhang, L., Zhou, W., Chen, Q., Chen, Y., Zheng, S., Duan, Z., & Li, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8703 · Cited by 17 · see citing works
Hou-Gang, L., You, P., Xia, Y., Cai, Y., Tu, Y., Wang, M., Song, W., Quan, T.-M., Ren, H.-Y., Yan-wen, L., et al. (2020) · Current Medical Science · doi:10.1007/s11596-020-2211-3 · Cited by 16 · see citing works
Tan, J. L., Sidhu-Brar, S., Woodman, R. J., & Chinnaratha, M. A. (2022) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00842-y · Cited by 15 · see citing works
Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis
Giuli, L., Pallozzi, M., Venturini, G., Gasbarrini, A., Ponziani, F. R., & Santopaolo, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612754 · Cited by 17 · see citing works
Crosstalk in extrahepatic and hepatic system in NAFLD / NASH
Duan, Y., Yang, Y. Z., Zhao, S., Bai, Y., Yao, W., Gao, X., & Yin, J. (2024) · Liver International · doi:10.1111/liv.15967 · Cited by 16 · see citing works
Thongtan, T., Deb, A., Vutthikraivit, W., Laoveeravat, P., Mingbunjerdsuk, T., Islam, S. R., & Islam, E. A. (2022) · Indian Journal of Gastroenterology · doi:10.1007/s12664-021-01230-3 · Cited by 15 · see citing works
Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma
Simon, T. G., & Chan, A. T. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.06.002 · Cited by 15 · see citing works
Joshi, N., Kopec, A. K., Ray, J. L., & Luyendyk, J. P. (2016) · Toxicology · doi:10.1016/j.tox.2016.07.021 · Cited by 14 · see citing works
Liu, F., Zeng, J., Zhu, D., Zhang, R., Xu, X., Wang, M., Zhang, Y., Xia, H., & Feng, Z. (2017) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22342 · Cited by 14 · see citing works
Platelets: A review of their function and effects in liver diseases
Chen, H., Chen, X., & Wang, G. (2020) · Liver Research · doi:10.1016/j.livres.2020.08.002 · Cited by 13 · see citing works
Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development
Sánchez, P. S., Rigual, M. D. M., & Djouder, N. (2021) · Cancers · doi:10.3390/cancers13205045 · Cited by 13 · see citing works
da Silva, C. M., Ferrari, G. D., Alberici, L. C., Malaspina, O., & Moraes, K. C. M. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03717-7 · Cited by 13 · see citing works
Yang, Y., Li, W., Liu, C., Liu, J., Yang, L., Yue, W., Yang, L., Xue, R., Zhang, K., Zhang, H., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166754 · Cited by 12 · see citing works
Ipsen, D. H., Skat‐Rørdam, J., Svenningsen, M., Andersen, M. V., Latta, M. R., Buelund, L. E., Lintrup, K., Skaarup, R., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13549 · Cited by 12 · see citing works
Jin, J., Cheng, K., Chen, M.-R., Liang, H., & Zhang, W.-G. (2025) · International Journal on Biological Sciences · doi:10.7150/ijbs.117394 · Cited by 14 · see citing works
- Authors
- Yoshida, S., Ikenaga, N., Liu, S. B., Peng, Z.-W., Chung, J., Sverdlov, D. Y., Miyamoto, M., Kim, Y. O., Ogawa, S., Arch, R. H., Schuppan, D., & Popov, Y.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Pfizer (United States) (US)
- Corresponding author
- Popov, Yury
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 147
- Issue
- 6
- Pages
- 1378-1392
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2121815683
- Cited by
- 164
- References
- 36
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 13 · 2023: 15 · 2022: 18 · 2021: 15 · 2020: 17 · 2019: 14 · 2018: 5 · 2017: 21 · 2016: 10 · 2015: 8 · 2014: 1
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Tokyo Women's Medical University
- Takeda Pharmaceuticals International
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Keywords
- platelet-derived growth factor beta, hepatic stellate cell activation, biliary fibrosis, liver fibrosis, platelets, low-dose aspirin, platelet depletion, CD41, alpha-smooth muscle actin, collagen deposition, fibrosis biomarkers
- MeSH terms
- ATP-Binding Cassette Sub-Family B Member 4, Adult, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Aspirin, Blood Platelets, Disease Models, Animal, Female, Humans, Liver Cirrhosis, Male, Mice, Inbred C57BL, Middle Aged, Platelet Aggregation Inhibitors, RNA, Messenger, Bile Ducts, Extrahepatic, Mice, Knockout, ATP Binding Cassette Transporter, Subfamily B, Proto-Oncogene Proteins c-sis, Hepatic Stellate Cells, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
